The case for immune‐based approaches in biliary tract carcinoma
Authors:
Open Access
- 14 May 2016
- journal article
- review article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 64 (5) , 1785-1791
Abstract
Biliary tract cancers (BTC) comprise a group of uncommon malignancies in which the standard therapies are minimally effective and evolve slowly. Like the majority of gastrointestinal cancers, with some notable exceptions, the impact of immune‐based approaches has yet to be seen. However, the etiological background of BTC—overlapping in almost every known causative or associated factor with inflammation—provides a strong clue that these approaches may have an impact in this group of diseases. This review covers what we currently know about the role of the immune system in the etiology of BTC, highlighting differences by subtype, and pointing to the therapeutic opportunities currently entering the clinic or about to do so. (Hepatology 2016;64:1785‐1791)Keywords
Funding Information
- Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research
This publication has 48 references indexed in Scilit:
- Cholangiocarcinomas can originate from hepatocytes in miceJournal of Clinical Investigation, 2012
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010
- Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responsesBritish Journal of Cancer, 2009
- Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infectionHepatology, 2008
- HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significanceOncogene, 2008
- Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligandsTissue Antigens, 2008